ORABASE HCA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Orabase Hca, and what generic alternatives are available?
Orabase Hca is a drug marketed by Colgate and is included in one NDA.
The generic ingredient in ORABASE HCA is hydrocortisone acetate. There are sixty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the hydrocortisone acetate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORABASE HCA?
- What are the global sales for ORABASE HCA?
- What is Average Wholesale Price for ORABASE HCA?
Summary for ORABASE HCA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 14 |
| Patent Applications: | 4,041 |
| DailyMed Link: | ORABASE HCA at DailyMed |
Recent Clinical Trials for ORABASE HCA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| British University In Egypt | PHASE2 |
| University of Palermo | PHASE2 |
| Dar Al Uloom University | PHASE2 |
US Patents and Regulatory Information for ORABASE HCA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colgate | ORABASE HCA | hydrocortisone acetate | PASTE;TOPICAL | 083205-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
